GWPH

Gw Pharma ADR

Trading Strategies

2,300 Reasons Pot Stocks Can Make You Rich in 2018

by

Many of these stocks proved resilient during last week's stock market correction, such as GW Pharmaceuticals Inc., Scotts Miracle-Gro Co., and Microsoft Corp.

In fact, the top weed stocks dipped far less than those in more traditional industries.

And their one-day market comeback on Tuesday outpaced anything we saw in autos, retail, or even blue-chip tech.

Days like that remind me of how ridiculous the mid-2017 mainstream media decrees that investors were burned out on pot stocks were. Those folks somehow believed that the excitement was gone and would not return.

So, while the darlings of Wall Street struggled to make back a fraction of their losses, there were significant success stories coming from places like – you guessed it – California's cannabis sector.

The proof points are all right there. This frontier industry keeps making your investment portfolio get fatter and fatter.

I'm looking at thousands of mini catalysts coming your way.

Let me show you...

Marijuana Industry

GW Reports Earnings Monday, but There's a Much More Profitable Date in Its Near Future

by

We're getting some big news today.

That's when GW Pharmaceuticals, one of the legal marijuana stocks we follow here, is reporting its first-quarter 2018 results.

GW Pharma's share price is up 211.3% in the last two years, more than quadruple the performance of the S&P 500 over the same stretch.

Now, GW has disappointed over the past few quarters. In fact, the company posted an earnings-per-share loss of $2.08 for third-quarter 2017. That was 29% below the consensus of the seven analysts who follow it. And Wall Street punished it to the tune of 7% the day those results were released.

And we can expect to see a similar dip if GW again misses expectations on Monday. And if it does, you should see it as an opportunity to buy on the dip and get it at a discount.

That's because we're invested here for the long haul – not quarter-to-quarter results – as GW works to get its cannabis-based prescription drugs in American pharmacies.

When it comes to those marijuana-based drugs – and all the profits and share-price gains they'll soon deliver – there's a date that's much more important to us than Feb. 5.

And it's approaching fast...

Marijuana Industry

This Cannabis-Friendly Cloud Just Grew 93%

by

The legal cannabis sector is no longer the "Wild West"-style marketplace it was back in, say, 2013, but there's still plenty of volatility compared with the placid broader markets.

Then again, that's why the right pot stocks reward forward-thinking investors with triple- and quadruple-digit gains. In fact, there's a bevy of micro- and small-cap companies, any one of which could be the next mega-cap blockbuster – the long-sought-after "Starbucks of weed" or "Facebook of pot."

My Nova-X Report's Roadmap to Marijuana Millions model portfolio is chock full of those kinds of stocks. Right now my paid-up members are sitting on gains of 915%… 520.6%… 442.7%… and five more triple-digit winners.

But I don't want to leave anyone with the impression that the only way to make a killing on pot stocks is to buy small, volatile companies. The gains from my Scotts Miracle-Gro and GW Pharmaceuticals recommendations prove that just isn't the case.

Then there's the company I want to tell you about today.

It isn't likely to quadruple your money quickly, but you'll likely smash the market with double- and even triple-digit gains, and it pays a dividend that puts you way out ahead of inflation and low interest rates, too.

What's more, all kinds of small legal cannabis companies are beating a path to its door for help with a very tricky problem...

Marijuana Industry

The Opioid Crisis Is Now a National "Public Health Emergency," and This One Company Could Help End It

by

Thanks to legal recreational use of marijuana about to launch in California and nationwide up in Canada, sometimes it's easy to forget where we got started here.

Legal marijuana first came to my attention because of the "War on Pain."

Let me explain…

In a study a year or so ago, the National Institutes of Health (NIH) found that about 11% of Americans suffered from debilitating pain. Other sources say the number of this country's pain sufferers may run as high as 50 million.

But I don't need statistics to know that millions of Americans suffer from serious pain problems.

I do so myself – and so do many of my friends and family members.

And that has turned the market for pain medication into a huge business. According to market researcher VisionGain, the worldwide business for pain drugs is worth about $68 billion right now.

Other studies say it's even bigger.

Equally huge is the nation's opioid crisis.

President Donald Trump has declared the opioid crisis a "public health emergency," and a White House commission has released its final report on the epidemic, calling for more drug courts, greater training for doctors, and penalties for insurers who do not cover addiction treatment.

The number of opioid-related deaths rose 75%, from roughly 20,000 in 2010 to 35,000 in 2015. In other words, opioid-based drugs kill more than 100 Americans every day.

This surge in the number of pain sufferers – coupled with the snapback against the prescription of opioid drugs – has opened the door to a wholly new approach to pain treatment.

I'm talking about medical marijuana and all its derivatives.

And there's one company, in particular, that you should be watching...